Brexit Impact Statement
As the manufacturer and supplier of an essential wound care treatment BioMonde have been continually monitoring the United Kingdom’s exit from the European Union until the transition period ends on the 1st of January 2021. We can provide reassurance that our supply chain will not be impacted. We do not believe that the supply of Larval Therapy will be interrupted within the UK mainland.
Republic of Ireland
We have been advised that the Department of Health (Ireland) are treating larvae as a special exception to the Exempt Medicinal Product classification and delivery of larvae will not be accepted in the ROI from the UK from the 1st of January 2021. BioMonde, as the largest supplier of medicinal larvae in Europe will continue to supply Republic of Ireland customers from our manufacturing site in Germany. Orders will still be processed in our UK head office as normal but will be sent directly to the ROI from Germany.
BioMonde are continuing to monitor the outcome of a trade exit deal and expect to be able to supply to Northern Ireland without import delays. In the event that a Brexit no deal, or an unfavourable trade deal is reached BioMonde will supply NI from our manufacturing site in Germany to ensure no interruptions or delays to patients receiving the treatment they require.
If you have any queries about the impact in receiving larvae due to Brexit please contact us at 0345 230 1810 or via email@example.com